Dacarbazine is used for: Metastatic melanoma; Hodgkin's disease; Soft tissue sarcoma.
Recorded in the NepalDoc medicine catalog for Dacarbazine.
Dacarbazine for Injection is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents.
From the U.S. FDA-approved label for Dacarbazine. Full label: DailyMed.
Dacarbazine for Injection is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents.
From the U.S. FDA-approved label for Dacarbazine. Full label: DailyMed.
Malignant Melanoma The recommended dosage is 2 to 4.5 mg/kg/day for 10 days. Treatment may be repeated at 4 week intervals. 2 An alternate recommended dosage is 250 mg/square meter body surface/day IV for 5 days.
Directions from the U.S. FDA-approved label for Dacarbazine — your doctor or pharmacist may advise differently.
Dacarbazine for injection is contraindicated in patients who have demonstrated a hypersensitivity to it in the past.
Excerpt from the U.S. FDA-approved label for Dacarbazine. Talk to a pharmacist or doctor before use.
Hemopoietic depression is the most common toxicity with dacarbazine for injection and involves primarily the leukocytes and platelets, although anemia may sometimes occur. Leukopenia and thrombocytopenia may be severe enough to cause death. The possible bone marrow depression requires careful monitoring of white blood cells, red blood cells, and platelet levels. Hemopoietic toxicity may warrant temporary suspension or cessation of therapy with dacarbazine for injection. Hepatic toxicity accompanied by hepatic vein thrombosis and hepatocellular necrosis resulting in death, has been reported.
Warnings and precautions excerpt from the U.S. FDA-approved label for Dacarbazine — not a complete list. Talk to a pharmacist or doctor before use.
Symptoms of anorexia, nausea, and vomiting are the most frequently noted of all toxic reactions. Over 90% of patients are affected with the initial few doses. The vomiting lasts 1 to 12 hours and is incompletely and unpredictably palliated with phenobarbital and/or prochlorperazine. Rarely, intractable nausea and vomiting have necessitated discontinuance of therapy with dacarbazine for injection.
Excerpt from the U.S. FDA-approved label for Dacarbazine — not a complete list. Talk to a pharmacist or doctor about side effects.
Store in a refrigerator 2° to 8°C (36° to 46°F). Use within 8 hours of reconstitution. Protect from light. DISCARD UNUSED PORTION. Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex.
Storage information from the U.S. FDA-approved label for Dacarbazine.
What is Dacmed?
Dacmed 200mg Injection is a Dacarbazine medicine made by United Biotech. It comes as 200mg Injection.
What is Dacmed used for?
Dacarbazine is used for Metastatic melanoma, Hodgkin's disease, Soft tissue sarcoma.
What is the generic name of Dacmed?
The generic name of Dacmed is Dacarbazine.
What are the side effects of Dacarbazine?
Symptoms of anorexia, nausea, and vomiting are the most frequently noted of all toxic reactions. Over 90% of patients are affected with the initial few doses. The vomiting lasts 1 to 12 hours and is incompletely and unpredictably palliated with phenobarbital and/or prochlorperazine.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
